ClinicalTrials.gg
CompletedNCT03189914Updated Dec 6, 2023Results posted

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

A Phase 1/2 interventional study of RX-3117 in Metastatic Pancreatic Cancer, sponsored by Processa Pharmaceuticals. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Processa Pharmaceuticals · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
658th of 1,573
46 · median 37
Started
2017
with 100 others
Phase 1/2
222 of 1,850
42 open now
Registered
1,072nd of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 658th largest by enrollment of the 1,573 interventional ones that give a count, is one of 101 that started in 2017, is one of 222 in phase 1/2, and was the 1,072nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.

Read the detailed description

This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. The recommended phase 2 dose (RP2D) and schedule of RX-3117, in combination with Abraxane®, will be determined based on the safety profile, dose modification, and pharmacokinetics (PK). Phase 1 will be conducted using a combination of the single agent maximum tolerated dose (MTD) for RX-3117 and the Abraxane dose as per the package insert for patients with pancreatic cancer in combination with gemcitabine.

After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy. Approximately 10 subjects will participate in the Stage 1 at the dose identified in Phase 1 (RP2D). Subjects will be treated for up to 8 cycles of combined therapy. An interim analysis will be conducted after 10 evaluable subjects have been treated at the RP2D, have completed a minimum of 4 cycles of therapy, or have discontinued therapy due to progressive disease before completing 4 cycles. If an adequate number of Responders are observed out of the initial 10 evaluable subjects, then 40 additional subjects will be enrolled to participate in Stage 2. Subjects will be treated for up to 8 cycles of combined therapy.

03

Conditions studied

  • Metastatic Pancreatic Cancer

Keywords

  • pancreatic cancer
  • Abraxane
  • first line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease Related

  1. Subject has confirmed histologic or cytologic evidence of pancreatic cancer and has no prior treatment for metastatic pancreatic cancer.
  2. Subject has using (RECIST) v 1.1.
  3. Subject has a of at least 3 months.
  4. Subject has an (ECOG) performance status 0 or 1.

    Demographic

  5. Males or females ≥ 18 years of age
  6. Subject must be able to swallow capsules
  7. Subject must have adequate venous access for intravenous (IV) infusion

    Laboratory

  8. Subject has ≥ 9.0 g/dL at Screening
  9. Subject has (ANC) ≥ 1.5 x 109/L at Screening
  10. Subject has count ≥ 100 x 109/L at Screening
  11. Subject has serum creatinine ≤ 1.5 times the (ULN) at Screening. Subjects with serum creatinine levels > 1.5 times the ULN must have a 24-hour urine ≥ 60 mL/min
  12. Subject has serum ≤ 1.5 times the ULN (except in subjects with Gilbert's Syndrome who must have serum bilirubin \< 3.0 x ULN)
  13. Subject has (AST; SGOT) and alanine aminotransferase (ALT; SGPT) ≤ 2.5 times the ULN (OR, AST and ALT ≤ 5 times the ULN in the presence of known liver metastases)
  14. Subject has alkaline phosphatase ≤ 2.5 times the ULN (OR ≤ 5 times the ULN in the presence of known liver or bone metastases)
  15. Subject has normal coagulation parameters ( [PT] and/or international normalized ratio [INR], and partial thromboplastin time [PTT] within normal limits [\<1.2 x ULN])
  16. Subject has potassium concentration within normal range, or correctable with supplements.
  17. Oxygen saturation by pulse oximetry ≥ 92% at rest.
  18. For women of : Negative serum pregnancy test during screening and negative serum or urine pregnancy test at start of study therapy (Cycle1 Day 1).

    Reproductive

  19. For female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol-recommended method of from the screening visit throughout the study treatment period and for 30 days following the last dose of study drug.
  20. Female subjects of non-childbearing potential defined as having amenorrhea for at least 24 consecutive months, a documented hysterectomy, or a documented bilateral oophorectomy)
  21. For fertile male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use a protocol-recommended method of contraception from the start of study therapy throughout the study treatment period and for 30 days following the last dose of study drug and to refrain from sperm donation from the start of study treatment throughout the study treatment period and for 30 days following the last dose of study drug.

    Ethical

  22. In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's cancer.
  23. Before any study-specific procedure, the appropriate written must be obtained

Exclusion criteria

Exclusion Criteria:

Disease Related

  1. Subject has primary brain tumors or clinical evidence of active
  2. Subject has undergone major surgery within 4 weeks of the start of study treatment. Laparoscopy and central venous catheter placement are not considered major surgery

    Medications

  3. Subject has a history of systemic use within 7 days before Day 1 of Cycle 1

    General

  4. Subject has an active infection requiring parenteral or oral antibiotics within 2 weeks before planned start of study therapy
  5. Subject has uncontrolled diabetes as assessed by the investigator
  6. Subject has a second other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers treated with curative intent and no known active disease within 3 years before planned start of study therapy
  7. Subject has an active infection of , or
  8. Female subjects who are pregnant, planning a pregnancy or breast feeding during the study
  9. Subject has a high cardiovascular risk, including, but not limited to, subjects with congestive heart failure ( [NYHA] Class III or IV), cardiac arrhythmia, unstable angina, coronary stenting or acute coronary syndromes within 6 months before planned start of study therapy or r myocardial infarction within one year before planned start of study therapy
  10. Criterion removed
  11. Subject has a history of prior allogeneic bone marrow progenitor cell or solid organ transplantation.
  12. Subject has known acute or chronic pancreatitis.
  13. Subject has persistent diarrhea, malabsorption, or known sub-acute bowel obstruction ≥ Grade 2, despite medical management.
  14. Subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery and bariatric surgery)
  15. All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], or neurotoxicity [Grade 1 or 2 permitted], or anemia [Grade 2 permitted])
  16. Subject has any other medical, psychiatric, or social condition, which in the opinion of the investigator, would preclude participation in the study, pose an undue medical hazard, interfere with the conduct of the study, or interfere with interpretation of the study results
  17. Subject has a history of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary pneumonitis or multiple allergies. Any lung disease that may interfere with the detection or management of suspected drug-related pulmonary toxicity.
  18. Subject is currently enrolled in any other clinical protocol or trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug.
  19. Subject has a history of hypersensitivity to RX-3117, gemcitabine, azacytidine cytosine arabinoside, paclitaxel, nab-paclitaxel, or their .
  20. Subject is unwilling or unable to comply with study requirements or planned unavailability for follow-up assessments.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    RX-3117 + Abraxane

    RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle. Abraxane: 75 - 125 mg/m\^2, infused once per week for 3 weeks. 1 washout week/ cycle.

    Drug: RX-3117

Interventions

  • DrugRX-3117

    RX-3117 will be administered orally in combination with Abraxane.

    Also known as: Abraxane

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2)

    Number of participants who experienced a treatment-related adverse event

    Time frame: 9 months

  2. Number of Participants With Clinical Laboratory Abnormalities (Phase 1 and 2)

    Participants with adverse events coded using the MedDRA Dictionary (Version 20.0) to Investigations. Due to the underlying disease, not all abnormal labs are reported.

    Time frame: 9 months

  3. Number of Participants With Vital Sign Abnormalities (Phase 1 and 2)

    Number of participants with clinically significant vital sign abnormalities (Phase 1 and 2) including heart rate, respiration rate, and blood pressure

    Time frame: 9 months

  4. Number of Participants With Electrocardiogram (ECG) Abnormalities (Phase 1 and 2)

    Number of participants with clinically significant ECG abnormalities (Phase 1 and 2)

    Time frame: 1 month

  5. Number of Dose-limiting Toxicities (DLTs) (Phase 1)

    Time frame: 4 weeks

  6. Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2)

    Participants must have progression Free Survival (PFS) \> 4 months or objective clinical response (complete or partial response).

    Time frame: 9 months

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 (Phase 1 and Phase 2) - Day 1

    Time frame: Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)

  2. Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 1

    Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)

  3. Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 1

    Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)

  4. Overall Response Rate [ORR] (Phase 1 and Phase 2)

    Overall Response Rate will be based on the RECIST v1.1 and is defined as the percentage of subjects meeting criteria of Complete Response (CR) or Partial Response (PR). CR or PR must be confirmed at least 4 weeks after the date of the original CR or PR.

    Time frame: Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks

  5. Time to Response [TTR] (Phase 1)

    Time frame: Up to 32 weeks

  6. Duration of Response [DOR] (Phase 1 and Phase 2)

    Duration of response is defined as the time from documentation of response to disease progression.

    Time frame: Up to 32 weeks

  7. Progression-free Survival [PFS] (Phase 1)

    Progression Free Survival defined as the percentage of subjects who are alive in the study and not in progression.

    Time frame: Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks

  8. Time to Progression (Phase 2)

    Time to Progression defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression.

    Time frame: Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks

  9. Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 and Abraxane® (Phase 1 and Phase 2) - Day 15

    Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)

  10. Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane® (Phase 1 and Phase 2) - Day 1

    Time frame: Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)

  11. Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane®(Phase 1 and Phase 2) - Day 15

    Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)

  12. Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 15

    Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)

  13. Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 1

    Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)

  14. Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 15

    Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)

  15. Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 15

    Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)

  16. Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 1

    Time frame: Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)

  17. Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15

    Time frame: Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)

Other outcomes

  1. Exploratory Measurement of Protein Biomarkers Related to RX-3117 or Pancreatic Cancer (Phase 1 and 2)

    Time frame: Baseline, and at 8, 6, 24, and 32 weeks

  2. Tumor Burden Response (Phase 2)

    Changes in tumor burden response via tumor marker measurement

    Time frame: Baseline, and at 8, 6, 24, and 32 weeks

  3. Quality of Life (QOL) (Phase 1 and 2)

    Weekly patient reported quality of life measures using validated QOL questionnaires

    Time frame: 9 months

07

Results

Posted Dec 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Started838
Completed cycle 1631
Completed14
Not completed734

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2)

Number of participants who experienced a treatment-related adverse event

Time frame:
9 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2)
ParticipantsRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (Phase 1 and 2)838
PrimaryNumber of Participants With Clinical Laboratory Abnormalities (Phase 1 and 2)

Participants with adverse events coded using the MedDRA Dictionary (Version 20.0) to Investigations. Due to the underlying disease, not all abnormal labs are reported.

Time frame:
9 months
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities (Phase 1 and 2)
ParticipantsRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Number of Participants With Clinical Laboratory Abnormalities (Phase 1 and 2)418
PrimaryNumber of Participants With Vital Sign Abnormalities (Phase 1 and 2)

Number of participants with clinically significant vital sign abnormalities (Phase 1 and 2) including heart rate, respiration rate, and blood pressure

Time frame:
9 months
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormalities (Phase 1 and 2)
ParticipantsRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Number of Participants With Vital Sign Abnormalities (Phase 1 and 2)00
PrimaryNumber of Participants With Electrocardiogram (ECG) Abnormalities (Phase 1 and 2)

Number of participants with clinically significant ECG abnormalities (Phase 1 and 2)

Time frame:
1 month
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities (Phase 1 and 2)
ParticipantsRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Number of Participants With Electrocardiogram (ECG) Abnormalities (Phase 1 and 2)00
PrimaryNumber of Dose-limiting Toxicities (DLTs) (Phase 1)
Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Dose-limiting Toxicities (DLTs) (Phase 1)
ParticipantsRX-3117 + Abraxane
Number of Dose-limiting Toxicities (DLTs) (Phase 1)0
PrimaryNumber of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2)

Participants must have progression Free Survival (PFS) \> 4 months or objective clinical response (complete or partial response).

Time frame:
9 months
Reported as:
Count of participants · Participants
Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2)
ParticipantsRX-3117 + Abraxane Phase 2
Number of Participants With Progression Free Survival (PFS) and/or Objective Clinical Response (Phase 2)17
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 (Phase 1 and Phase 2) - Day 1
Time frame:
Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 (Phase 1 and Phase 2) - Day 1
ng*hr/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 (Phase 1 and Phase 2) - Day 110500 ± 64908780 ± 4460
SecondaryTime to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 1
Time frame:
Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Reported as:
Mean · hr
Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 1
hrRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 12.3 ± 0.894.51 ± 6.18
SecondaryMaximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 1
Time frame:
Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Reported as:
Mean · ng/mL
Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 1
ng/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 11120 ± 516947 ± 422
SecondaryOverall Response Rate [ORR] (Phase 1 and Phase 2)

Overall Response Rate will be based on the RECIST v1.1 and is defined as the percentage of subjects meeting criteria of Complete Response (CR) or Partial Response (PR). CR or PR must be confirmed at least 4 weeks after the date of the original CR or PR.

Time frame:
Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Reported as:
Count of participants · Participants
Overall Response Rate [ORR] (Phase 1 and Phase 2)
ParticipantsRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Overall Response Rate [ORR] (Phase 1 and Phase 2)27
SecondaryTime to Response [TTR] (Phase 1)
Time frame:
Up to 32 weeks
Reported as:
Median · weeks
Time to Response [TTR] (Phase 1)
weeksRX-3117 + Abraxane Phase 1
Time to Response [TTR] (Phase 1)23.6 (7.4 to 23.6)
SecondaryDuration of Response [DOR] (Phase 1 and Phase 2)

Duration of response is defined as the time from documentation of response to disease progression.

Time frame:
Up to 32 weeks
Reported as:
Median · weeks
Duration of Response [DOR] (Phase 1 and Phase 2)
weeksRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Duration of Response [DOR] (Phase 1 and Phase 2)NA (19.1 to NA)NA (16.1 to NA)
SecondaryProgression-free Survival [PFS] (Phase 1)

Progression Free Survival defined as the percentage of subjects who are alive in the study and not in progression.

Time frame:
Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Reported as:
Median · weeks
Progression-free Survival [PFS] (Phase 1)
weeksRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Progression-free Survival [PFS] (Phase 1)13.8 (7.0 to NA)23.3 (15.1 to 31.1)
SecondaryTime to Progression (Phase 2)

Time to Progression defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression.

Time frame:
Every 8 weeks until progression or discontinuation, whichever came first, assessed up to 32 weeks
Reported as:
Median · weeks
Time to Progression (Phase 2)
weeksRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Time to Progression (Phase 2)13.8 (7.0 to NA)23.4 (15.1 to 32.6)
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 and Abraxane® (Phase 1 and Phase 2) - Day 15
Time frame:
Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 and Abraxane® (Phase 1 and Phase 2) - Day 15
ng*hr/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Area Under the Plasma Concentration Versus Time Curve (AUC) of RX-3117 and Abraxane® (Phase 1 and Phase 2) - Day 151820 ± 5103160 ± 1490
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane® (Phase 1 and Phase 2) - Day 1
Time frame:
Cycle 1 Day 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane® (Phase 1 and Phase 2) - Day 1
ng*hr/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane® (Phase 1 and Phase 2) - Day 15560 ± 24105290 ± 2120
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane®(Phase 1 and Phase 2) - Day 15
Time frame:
Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane®(Phase 1 and Phase 2) - Day 15
ng*hr/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Area Under the Plasma Concentration Versus Time Curve (AUC) of Abraxane®(Phase 1 and Phase 2) - Day 154020 ± 17103670 ± 2080
SecondaryTime to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 15
Time frame:
Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Reported as:
Mean · hr
Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 15
hrRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Time to Maximum Observed Concentration [Tmax] of RX-3117 (Phase 1 and Phase 2) - Day 151.84 ± 0.413.75 ± 1.35
SecondaryTime to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 1
Time frame:
Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Reported as:
Mean · hr
Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 1
hrRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 10.71 ± 0.170.62 ± 0.10
SecondaryTime to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 15
Time frame:
Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Reported as:
Mean · hr
Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 15
hrRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Time to Maximum Observed Concentration [Tmax] of Abraxane® (Phase 1 and Phase 2) - Day 150.55 ± 0.060.69 ± 0.18
Other pre-specifiedExploratory Measurement of Protein Biomarkers Related to RX-3117 or Pancreatic Cancer (Phase 1 and 2)
Time frame:
Baseline, and at 8, 6, 24, and 32 weeks

Results for this outcome have not been posted.

Other pre-specifiedTumor Burden Response (Phase 2)

Changes in tumor burden response via tumor marker measurement

Time frame:
Baseline, and at 8, 6, 24, and 32 weeks

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (QOL) (Phase 1 and 2)

Weekly patient reported quality of life measures using validated QOL questionnaires

Time frame:
9 months

Results for this outcome have not been posted.

SecondaryMaximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 15
Time frame:
Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Reported as:
Mean · ng/mL
Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 15
ng/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Maximum Observed Concentration [Cmax] of RX-3117 (Phase 1 and Phase 2) - Day 15528 ± 166838 ± 329
SecondaryMaximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 1
Time frame:
Cycle 1 Days 1 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, 6, and 24 hours after administration)
Reported as:
Mean · ng/mL
Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 1
ng/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 14160 ± 27703940 ± 2320
SecondaryMaximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15
Time frame:
Day 15 (pre-infusion, post-infusion, pre-dose RX-3117, and 0.5, 1, 2, 4, and 6 hours after administration)
Reported as:
Mean · ng/mL
Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 15
ng/mLRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Maximum Observed Concentration [Cmax] of Abraxane (Phase 1 and Phase 2) - Day 154780 ± 23803320 ± 2330

Adverse events

Collected over Adverse event data were collected from Cycle 1 Day until Safety Follow Up (30 days after last dose). an average of 9 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RX-3117 + Abraxane Phase 10/8 (0%)3/8 (37.5%)8/8 (100%)
RX-3117 + Abraxane Phase 22/38 (5.3%)18/38 (47.4%)38/38 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
Febrile neutropeniaBlood and lymphatic system disorders1/81/38
AnaemiaBlood and lymphatic system disorders1/80/38
HyperbilirubinaemiaHepatobiliary disorders1/80/38
EmbolismVascular disorders1/80/38
Small intestinal obstructionGastrointestinal disorders0/82/38
Cholecystitis acuteHepatobiliary disorders0/82/38
NeutropeniaBlood and lymphatic system disorders0/81/38
Myocardial infarctionCardiac disorders0/81/38
Abdominal pain upperGastrointestinal disorders0/81/38
StomatitisGastrointestinal disorders0/81/38
Most frequent other events
Showing 10 of 64
Most frequent other events
EventRX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2
DiarrhoeaGastrointestinal disorders8/825/38
NauseaGastrointestinal disorders6/823/38
FatigueGastrointestinal disorders6/823/38
AlopeciaSkin and subcutaneous tissue disorders5/89/38
Abdominal painGastrointestinal disorders1/820/38
AnaemiaBlood and lymphatic system disorders2/819/38
VomitingGastrointestinal disorders4/811/38
Decreased appetiteMetabolism and nutrition disorders4/815/38
DizzinessNervous system disorders2/817/38
PruritusSkin and subcutaneous tissue disorders3/83/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)RX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2Total
Mean66 ± 70.566.3 ± 6666.3 ± 67
Sex: Female, Male
Sex: Female, Male(Participants)RX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2Total
Female51924
Male31922
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2Total
Hispanic or Latino156
Not Hispanic or Latino73239
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American044
White83442
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)RX-3117 + Abraxane Phase 1RX-3117 + Abraxane Phase 2Total
United States83846
08

Study locations

10 sites
  • Rexahn Site
    Tucson, Arizona 85724, United States
  • Rexahn Site
    Weeki Wachee, Florida 34607, United States
  • Rexahn Site
    Joliet, Illinois 60435, United States
  • Rexahn Site
    Skokie, Illinois 60077, United States
  • Rexahn Site
    Lexington, Kentucky 40503, United States
  • Rexahn Site
    Boston, Massachusetts 02115, United States
  • Rexahn Site
    New York, New York 10065, United States
  • Rexahn Site
    Spartanburg, South Carolina 29303, United States
  • Rexahn Site
    Spokane, Washington 99202, United States
  • Rexahn Site
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Oct 2019, 23 months.

Results were first posted in Dec 2023, 4 years 2 months after primary completion.

Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 23 months is below that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2017
First posted
Jun 16, 2017
StartActual
Oct 2, 2017
Primary completionActual
Oct 1, 2019
CompletionActual
Nov 21, 2019
Results first posted
Dec 6, 2023
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03189914
Lead sponsor
Processa Pharmaceuticals
Responsible party
Sponsor
First posted
Jun 16, 2017
Start date
Oct 2, 2017
Primary completion
Oct 1, 2019
Completion
Nov 21, 2019
Results posted
Dec 6, 2023
Last update
Dec 6, 2023

Study contacts

Ely Benaim, MD
study director · Rexahn Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion